News and Trends 26 May 2023
Novartis buys AVROBIO cystinosis gene therapy program for $87.5M
AVROBIO, Inc., a clinical-stage gene therapy company working to free people from a lifetime of genetic disease, has agreed to sell its investigational hematopoietic stem cell (HSC) gene therapy program…